These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 18711176)

  • 1. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.
    Anderson JR; Cain KC; Gelber RD
    J Clin Oncol; 2008 Aug; 26(24):3913-5. PubMed ID: 18711176
    [No Abstract]   [Full Text] [Related]  

  • 2. Methods for the analysis of time to failure data.
    Prentice RL
    Prog Clin Biol Res; 1983; 132E():69-79. PubMed ID: 6647490
    [No Abstract]   [Full Text] [Related]  

  • 3. Defining survival as an outcome measure in amyotrophic lateral sclerosis.
    Gordon PH; Corcia P; Lacomblez L; Pochigaeva K; Abitbol JL; Cudkowicz M; Leigh PN; Meininger V
    Arch Neurol; 2009 Jun; 66(6):758-61. PubMed ID: 19506136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Various pitfalls in cancer clinical trials].
    Sakamoto J; Matsui T; Kodera Y
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):161-70. PubMed ID: 19223730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
    Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
    Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates.
    Jain A; Phillips RM; Scally AJ; Lenaz G; Beer M; Puri R
    Urology; 2009 May; 73(5):1083-6. PubMed ID: 19232688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reporting of time-to-event end points and tracking of failures in randomized trials of radiotherapy with or without any concomitant anticancer agent for locally advanced head and neck cancer.
    Le Tourneau C; Michiels S; Gan HK; Siu LL
    J Clin Oncol; 2009 Dec; 27(35):5965-71. PubMed ID: 19805677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual patient data analysis to assess modifications to the RECIST criteria.
    Bogaerts J; Ford R; Sargent D; Schwartz LH; Rubinstein L; Lacombe D; Eisenhauer E; Verweij J; Therasse P;
    Eur J Cancer; 2009 Jan; 45(2):248-60. PubMed ID: 19095437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising importance of patient-reported outcomes.
    Atherton PJ; Sloan JA
    Lancet Oncol; 2006 Nov; 7(11):883-4. PubMed ID: 17081911
    [No Abstract]   [Full Text] [Related]  

  • 11. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
    J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
    Ohorodnyk P; Eisenhauer EA; Booth CM
    Eur J Cancer; 2009 Sep; 45(13):2249-52. PubMed ID: 19545996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bilateral Wilms' tumor: the need to improve outcomes.
    Ehrlich PF
    Expert Rev Anticancer Ther; 2009 Jul; 9(7):963-73. PubMed ID: 19589035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI as an outcome in multiple sclerosis clinical trials.
    Tenser RB
    Neurology; 2009 Dec; 73(22):1933-4; author reply 1934. PubMed ID: 19949044
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular imaging to select cancer therapy and evaluate treatment response.
    Mankoff DA
    Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):181-92. PubMed ID: 19293766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells.
    Rücker G; Schwarzer G; Carpenter J; Olkin I
    Stat Med; 2009 Feb; 28(5):721-38. PubMed ID: 19072749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
    Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
    Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key symptom domains to be assessed in fibromyalgia (outcome measures in rheumatoid arthritis clinical trials).
    Choy EH; Mease PJ
    Rheum Dis Clin North Am; 2009 May; 35(2):329-37. PubMed ID: 19647146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immortal person-time in studies of cancer outcomes.
    Lash TL; Cole SR
    J Clin Oncol; 2009 Aug; 27(23):e55-6. PubMed ID: 19597013
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
    Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
    Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.